Although the contribution of mutant NRAS and BRAF to MM progression appears to be less common than melanoma of the skin, more components in the MAPK pathway of MM tend to undergo mutations or copy number changes, rendering inhibition of MAPK signaling transduction more challenging. This evidence concerns the gene BRAF and Miyoshi myopathy.